Ocular Therapeutix (OCUL) Notes Payables (2013 - 2023)

Ocular Therapeutix's Notes Payables history runs 9 years deep, the most recent figure standing at $2.1 million for Q2 2023.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $2.1 million in Q2 2023; TTM through Jun 2023 was $2.1 million, a N/A change from a year earlier, with the FY2020 full-year figure at $8.3 million, changed N/A from the prior year.
• Notes Payables eased to $2.1 million in Q2 2023 per OCUL's latest filing, from $8.3 million in the prior quarter.
• Across five years, Notes Payables topped out at $8.3 million in Q4 2020 and bottomed at $2.1 million in Q1 2020.
• The 3-year median for Notes Payables is $5.2 million (2020), against an average of $5.2 million.
• Biggest YoY gain for Notes Payables was 299.71% in 2021; the steepest drop was 299.71% in 2021.
• Year by year, Notes Payables stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then plunged by 74.87% to $2.1 million in 2023.
• Per Business Quant, the three latest OCUL Notes Payables figures stand at $2.1 million (Q2 2023), $8.3 million (Q1 2021), and $8.3 million (Q4 2020).